Matthew Mills, MD
Ophthalmology · Reno, NVNPI 1407843782
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,420 of the $14,785 with a category attached, or 63.7%. 31 manufacturers reported payments, led by Alcon at 44.6% of the total. 2025 is the largest year on record at $5,852, 4.2 times the $1,398 reported in 2019. Among ophthalmology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $51.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$7K
- Glaukos Corporation$2K
- Rayner Intraocular Lenses Limited$1K
- Johnson & Johnson Surgical Vision, Inc.$777
- AbbVie$681
- Sight Sciences, Inc.$535
- plus $3K from 25 others
Across 3 payments — averaging $6666.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$20K
What the payments were for
- Consulting fees$4,00027%
- Speaking & faculty fees$1,0627%
- Travel & lodging$3032%
- Food & beverage$9,42064%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 63 | $6,587 |
| Glaukos Corporation | 28 | $1,952 |
| Rayner Intraocular Lenses Limited | 5 | $1,097 |
| Johnson & Johnson Surgical Vision, Inc. | 34 | $777 |
| AbbVie(2 entities) | 38 | $681 |
| Sight Sciences, Inc. | 16 | $535 |
| Carl Zeiss Meditec USA, Inc. | 4 | $401 |
| Sun Pharmaceutical Industries Inc. | 15 | $314 |
| Oyster Point Pharma, Inc. | 10 | $306 |
| Novartis | 14 | $295 |
| Biotissue Holdings Inc. | 6 | $198 |
| Aerie Pharmaceuticals, Inc. | 3 | $184 |
| Rxsight Inc | 8 | $175 |
| Apellis Pharmaceuticals, Inc. | 3 | $157 |
| Ocular Therapeutix, Inc. | 2 | $151 |
| Mallinckrodt Hospital Products Inc. | 7 | $145 |
| Amgen | 1 | $125 |
| Hoffmann-la Roche Limited | 1 | $99 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $88 |
| Omeros Corporation | 4 | $67 |
| Dompe US, Inc. | 3 | $61 |
| Astellas Pharma US Inc | 2 | $57 |
| Ivantis, Inc | 2 | $51 |
| Kala Pharmaceuticals, Inc. | 3 | $51 |
| NEW World Medical,inc. | 4 | $47 |
| Bausch & Lomb Americas Inc. | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Alcon Research LLC | 1 | $37 |
| Harrow Eye, LLC | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORA System VerifEye$4,000
- LenSx$4,000
- OMIDRIA$1,037
- iDoseTR$763
- iDose$336
- Centurion$259
- OMNI$232
- Clareon$221
- Constellation$160
- Hydrus Microstent$150
- ReSTOR$137
- DEXTENZA$133
- iStent inject W$128
- KXL System$128
- Photrexa$128
- TEPEZZA$125
- Rhopressa$107
- Syfovre$100
How this compares
$14,785 in reported general payments places this provider in the 90th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 40 | $24,006 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $13,379 |
| VyzultaLatanoprostene Bunod | 25 | $10,862 |
| Timolol Maleate | 88 | $5,797 |
| Latanoprost | 351 | $4,632 |
| Brimonidine Tartrate | 38 | $3,529 |
| Travoprost | 18 | $2,548 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,646 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $902 |
| Prednisolone Acetate | 15 | $591 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $561 |
| ErythromycinErythromycin Base | 34 | $393 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $317 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 26 | $284 |
| Dorzolamide Hcl | 11 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $681 | $24,00640 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $45 | $10,86225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Reno
- Arshad KhananiReno$2M
- Steve ChangReno$75K
- Elena GeraymovychReno$14K
- Jamison EngleReno$6K
- Kevin GamettReno$6K
- Caleb MorrisReno$4K
- William DurantReno$4K
- Hardeep DhindsaReno$3K
- Peter FreemanReno$3K
- Xintong LiReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.